Emerging Targets in Lipid Metabolism for Cancer Therapy

Overview

Journal Trends Pharmacol Sci

Specialty Pharmacology

Date 2024 May 18

PMID 38762377

Authors

Alexander R Terry

Nissim Hay

Affiliations

Soon will be listed here.

Abstract

Cancer cells perturb lipid metabolic pathways for a variety of pro-tumorigenic functions, and deregulated cellular metabolism is a hallmark of cancer cells. Although alterations in lipid metabolism in cancer cells have been appreciated for over 20 years, there are no FDA-approved cancer treatments that target lipid-related pathways. Recent advances pertaining to cancer cell fatty acid synthesis (FAS), desaturation, and uptake, microenvironmental and dietary lipids, and lipid metabolism of tumor-infiltrating immune cells have illuminated promising clinical applications for targeting lipid metabolism. This review highlights emerging pathways and targets for tumor lipid metabolism that may soon impact clinical treatment.

Citing Articles

Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment.

Wan M, Pan S, Shan B, Diao H, Jin H, Wang Z Mol Cancer. 2025; 24(1):61.

PMID: 40025508 PMC: 11874147. DOI: 10.1186/s12943-025-02258-1.

Knockdown of HOXD13 in Oral Squamous Cell Carcinoma Inhibited its Proliferation, Migration, and Influenced Fatty Acid Metabolism.

Ma X, Zhang X, Li H, Mei S, Wang B, Guan S J Cancer. 2025; 16(1):214-226.

PMID: 39744569 PMC: 11660140. DOI: 10.7150/jca.102100.

[Progress in applications of ambient ionization mass spectrometry for lipids identification].

Wang X, Yin Y, Ouyang J, Na N Se Pu. 2024; 43(1):22-32.

PMID: 39722618 PMC: 11686479. DOI: 10.3724/SP.J.1123.2024.06007.

Unraveling lipid metabolism for acute myeloid leukemia therapy.

OBrien C, Jones C Curr Opin Hematol. 2024; 32(2):77-86.

PMID: 39585293 PMC: 11789610. DOI: 10.1097/MOH.0000000000000853.

USP11 promotes lipogenesis and tumorigenesis by regulating SREBF1 stability in hepatocellular carcinoma.

Xu Y, Zeng J, Liu K, Li D, Huang S, Fu S Cell Commun Signal. 2024; 22(1):550.

PMID: 39558331 PMC: 11572171. DOI: 10.1186/s12964-024-01926-x.

References

Xiao Y, Yang Y, Xiong H, Dong G . The implications of FASN in immune cell biology and related diseases. Cell Death Dis. 2024; 15(1):88. PMC: 10810964. DOI: 10.1038/s41419-024-06463-6. View

Terry A, Nogueira V, Rho H, Ramakrishnan G, Li J, Kang S . CD36 maintains lipid homeostasis via selective uptake of monounsaturated fatty acids during matrix detachment and tumor progression. Cell Metab. 2023; 35(11):2060-2076.e9. PMC: 11748917. DOI: 10.1016/j.cmet.2023.09.012. View

Li Y, Ran Q, Duan Q, Jin J, Wang Y, Yu L . 7-Dehydrocholesterol dictates ferroptosis sensitivity. Nature. 2024; 626(7998):411-418. PMC: 11298758. DOI: 10.1038/s41586-023-06983-9. View

Dmitrieva-Posocco O, Wong A, Lundgren P, Golos A, Descamps H, Dohnalova L . β-Hydroxybutyrate suppresses colorectal cancer. Nature. 2022; 605(7908):160-165. PMC: 9448510. DOI: 10.1038/s41586-022-04649-6. View

Jin Q, Yuan L, Boulbes D, Baek J, Wang Y, Gomez-Cabello D . Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res. 2010; 12(6):R96. PMC: 3046439. DOI: 10.1186/bcr2777. View

Fhu C, Ali A . Fatty Acid Synthase: An Emerging Target in Cancer. Molecules. 2020; 25(17). PMC: 7504791. DOI: 10.3390/molecules25173935. View

Liu Y, Gao G, Minna J, Williams N, Westover K . Loss of wild type KRAS in KRAS lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors. Lung Cancer. 2021; 153:73-80. PMC: 7897317. DOI: 10.1016/j.lungcan.2020.12.032. View

Alwarawrah Y, Hughes P, Loiselle D, Carlson D, Darr D, Jordan J . Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer. Cell Chem Biol. 2016; 23(6):678-88. PMC: 6443244. DOI: 10.1016/j.chembiol.2016.04.011. View

Luis G, Godfroid A, Nishiumi S, Cimino J, Blacher S, Maquoi E . Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biol. 2021; 43:102006. PMC: 8163990. DOI: 10.1016/j.redox.2021.102006. View

10.

Lim S, Wei J, Nguyen T, Shi H, Su W, Palacios G . Lipid signalling enforces functional specialization of T cells in tumours. Nature. 2021; 591(7849):306-311. PMC: 8168716. DOI: 10.1038/s41586-021-03235-6. View

11.

Volmer R, van der Ploeg K, Ron D . Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains. Proc Natl Acad Sci U S A. 2013; 110(12):4628-33. PMC: 3606975. DOI: 10.1073/pnas.1217611110. View

12.

Worthmann A, Ridder J, Piel S, Evangelakos I, Musfeldt M, Voss H . Fatty acid synthesis suppresses dietary polyunsaturated fatty acid use. Nat Commun. 2024; 15(1):45. PMC: 10762034. DOI: 10.1038/s41467-023-44364-y. View

13.

Hao J, Wang J, Guo H, Zhao Y, Sun H, Li Y . CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis. Nat Commun. 2020; 11(1):4765. PMC: 7505845. DOI: 10.1038/s41467-020-18565-8. View

14.

Dolgin E . A fat-blocking drug could help to fight metastatic cancer. Nature. 2023; . DOI: 10.1038/d41586-023-01648-z. View

15.

Vriens K, Christen S, Parik S, Broekaert D, Yoshinaga K, Talebi A . Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature. 2019; 566(7744):403-406. PMC: 6390935. DOI: 10.1038/s41586-019-0904-1. View

16.

Watt M, Clark A, Selth L, Haynes V, Lister N, Rebello R . Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med. 2019; 11(478). DOI: 10.1126/scitranslmed.aau5758. View

17.

Listenberger L, Han X, Lewis S, Cases S, Farese Jr R, Ory D . Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A. 2003; 100(6):3077-82. PMC: 152249. DOI: 10.1073/pnas.0630588100. View

18.

Menendez J, Vellon L, Mehmi I, Oza B, Ropero S, Colomer R . Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A. 2004; 101(29):10715-20. PMC: 490000. DOI: 10.1073/pnas.0403390101. View

19.

Doll S, Proneth B, Tyurina Y, Panzilius E, Kobayashi S, Ingold I . ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2016; 13(1):91-98. PMC: 5610546. DOI: 10.1038/nchembio.2239. View

20.

Ferrer M, Mourikis N, Davidson E, Kleeman S, Zaccaria M, Habel J . Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia. Cell Metab. 2023; 35(7):1147-1162.e7. PMC: 11037504. DOI: 10.1016/j.cmet.2023.05.008. View